One (1) year firm-fixed-price purchase order for preclinical assessment of naloxone adequacy to reverse polysubstance.

Active Purchase Order Awarded

Contract number
75F40126P00393
Awardee
Awarding agency
Obligated
$340,000

Award facts

Opportunity
  • 1292327 Solicitation number
Contract value 100% obligated
$340,000.00 Current and potential, with all options
Completion date 11% complete
Current and potential, with all options
Contracting staff
NAICS code
334516 Analytical Laboratory Instrument Manufacturing
PSC
AN12 Health R&D Services; Health Care Services; Applied Research
Set-aside
No set-aside
Competition
Not Competed · 1 offer Only One Source
Pricing
Firm Fixed Price
Place of performance
Silver Spring, MD 20903, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

About this award

Written by GovTribe AI ·

The Food and Drug Administration awarded a one-year firm-fixed-price purchase order to Charles River Laboratories, Inc. for $340,000 on September 25, 2026 to conduct preclinical assessment of naloxone adequacy to reverse polysubstance effects. Performance occurs in Silver Spring, Maryland, with an ultimate completion date of September 24, 2027. No set-aside applies to this order.

Quick answers

Who was awarded contract 75F40126P00393?

75F40126P00393 was awarded to Charles River Laboratories, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 25, 2026.

How much is contract 75F40126P00393 worth?

The government has obligated $340,000 on 75F40126P00393.

Was contract 75F40126P00393 competed?

The extent of competition for 75F40126P00393 was not competed. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login